GlassScriptPhysician profile
Josephine E Sims
NPI 1023430725
$11,056.87
in general payments reported to CMS, 2019-2025
44 companies · $771 in 2025
The $771 reported for 2025 was more than what 82% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,379 · 2022: $2,868 · 2023: $2,789 · 2024: $2,251 · 2025: $771.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,811.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,810.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,340.14 | 2021-2025 | |
| Novo Nordisk INC | $1,162.31 | 2021-2025 | Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $1,156.94 | 2021-2025 | Breztri, Farxiga, Airsupra |
| Glaxosmithkline, LLC. | $1,047.87 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $968.33 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $849.62 | 2022-2025 | |
| Pfizer INC. | $744.75 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $445.34 | 2021-2025 | Synjardy, Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $344.55 | 2021-2025 | Xifaxan, Trulance |
| Tris Pharma INC | $250.50 | 2022-2024 | Dyanavel Xr |
| Sanofi-Aventis U.S. LLC | $213.51 | 2021-2023 | |
| Endo Pharmaceuticals INC. | $194.91 | 2021-2022 | |
| Exact Sciences Corporation | $160.30 | 2023-2025 | Cologuard Collection Kit |
| Axsome Therapeutics, INC. | $150.62 | 2023-2025 | Auvelity |
| Biohaven Pharmaceuticals, INC. | $140.32 | 2021 |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $138.06 | 2021-2023 | Belsomra, Steglatro |
| Abbott Laboratories | $135.58 | 2022-2024 | Freestyle Libre, Freestyle Libre 3 |
| Janssen Pharmaceuticals, INC | $121.86 | 2021-2022 | |
| Amgen INC. | $114.68 | 2024 | Otezla, Repatha |
| Biohaven Pharmaceutical Holding Company LTD. | $110.77 | 2022 | |
| Ironwood Pharmaceuticals, INC | $108.90 | 2021-2022 | |
| Astellas Pharma US INC | $105.18 | 2023-2025 | Veozah, Myrbetriq |
| Esperion Therapeutics, INC. | $97.12 | 2021-2024 | Nexletol |
| Idorsia Pharmaceuticals US INC | $92.68 | 2022-2023 | Quviviq |
| Kowa Pharmaceuticals America, INC. | $87.34 | 2021-2024 | Seglentis, Livalo, Zoryve |
| Takeda Pharmaceuticals U.S.A., INC. | $86.64 | 2021-2025 | Trintellix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $81.64 | 2024-2025 | Caplyta |
| Philips North America LLC | $62.54 | 2022 | |
| Neurelis, INC. | $60.63 | 2025 | Valtoco |
| Almatica Pharma LLC | $58.14 | 2021-2022 | |
| Neos Therapeutics, LP | $53.58 | 2022-2023 | Adzenys Xr-Odt |
| Eisai INC. | $53.38 | 2021 | |
| Bausch Health US, LLC | $38.63 | 2022 | |
| Sumitomo Pharma America, INC. | $37.54 | 2023 | Gemtesa |
| Cranial Technologies, INC | $35.63 | 2024 | Doc Band |
| Phathom Pharmaceuticals, INC. | $34.73 | 2024-2025 | Voquezna |
| Seqirus USA INC | $31.39 | 2022-2023 | Flucelvax Quadrivalent, Fluad Quadrivalent |
| Horizon Therapeutics Plc | $27.99 | 2021-2022 | |
| Amarin Pharma, INC. | $21.55 | 2022 | |
| Supernus Pharmaceuticals, INC. | $20.09 | 2022 | |
| Dexcom, INC. | $18.48 | 2021 | |
| Sunovion Pharmaceuticals INC. | $18.37 | 2021 | |
| Amneal Pharmaceuticals LLC | $17.12 | 2024 | Unithroid |
| Sanofi Pasteur INC. | $16.62 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Josephine Sims listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.